IMMUNOHISTOCHEMICAL EXPRESSION OF CANCER STEM CELL MARKER (ALDH1) IN A PROSTATE CANCER

Journal Title: European Journal of Pharmaceutical and Medical Research - Year 2019, Vol 6, Issue 1

Abstract

Background: Cancer stem cells were identified in several cancers, including PCa, and have been proposed to explain the metastatic capacity, recurrence, and resistance to hormone, radio and chemotherapy in established cell lines from PCa origin, particularly from metastasis. Enzymatic assays and immunohistochemistry have identified several proteins and surface markers that are expressed by CSCs and may be used to identify them in patients. Aim of the study: To assess the immunohistochemical (IHC) expression patterns of the ALDHmarker in PCa, BPH and in apparently normal looking prostate tissue. Methods: A cross-sectional Study carried out at department of histopathology and forensic medicine at Al-Mustansirya medical college and teaching lab of Al-Yarmook Teaching Hospital during a period of one year from (1st of august 2017 to 30th of July 2018). It involved 90 specimens; and these specimens were divided into the following: 60 of them were collected retrospectively depending on the archived files of patients diagnosed either with BPH (30 specimens) or with PCa (30 specimens) in the years 2016 and 2017 in Al-Yarmook Teaching Hospital and in the private labs. The other 30 specimens of normal prostatic tissue were collected prospectively from autopsy presented in forensic medicine directorate during the first three months of 2018. All patients diagnosed with BPH or PCa during 2016 and 2017 were included without any exclusion. Positive control: Human gallbladder tissue for ALDH marker with each run. Results: The mean age of the patients was 73.71 ± 8.15 years. The highest proportion of specimens of PCa (Group A) was graded ≤ 7 by Gleason Grading System (53.3%). There were significant associations (P < 0.05) between all these CSC marker results and prevalence of PCa. Positive ALDH marker result was significantly associated (P=0.024) with high Gleason Grading System. Conclusion: ALDH1 is significantly expressed in prostate carcinomas, and more likely so in cases with Gleason grading system 8.

Authors and Affiliations

Hadeel Ismail Mohsen

Keywords

Related Articles

CYANOACRYLATES: AN OVERVIEW IN ITS APPLICATION AS A TISSUE ADHESIVE

The wound closure has been a matter of concern for the patients more than the surgery itself. Major reasons include the endless pain and the complications involved in the conventional tissue adhesion methods like sutures...

ROLE OF CYTOKINES(INF- Γ, IL-6, IL-10) IN THE PATHOGENESIS OF AUTOIMMUNE TYPE I DIABETES MELLITUS

Type I diabetes mellitus is an autoimmune disease; it is one of most serious and common metabolic disorders in children and adolescents, in which the body immune system destroys the insulin releasing beta cells. Thus, th...

STRESS-INDUCED IMMUNE-RELATED DISEASE AND HEALTH OUTCOME OF PHARMACY AND DENTISTRY STUDENTS-PILOT STUDY

Stress and its impact on health sciences students were broadly studied. In our knowledge, there was no studies conducted in United Arab Emirates to measure the stress and its effects on the immune responses among Pharmac...

ANTICANCER ACTIVITY OF THYMOQUINONE AND ALLICIN ON CANCER PROSTATE (PC3) AND COLON CANCER (CACO2) CELL LINES, IN VITRO STUDY

Thymoquinone and Allicine, natural products extracted from black seeds and garlic, respectively, are known as having anticancer activity. The activity of these two natural products was investigated on cancer prostate (PC...

ABRUPTIO PLACENTAE: INCIDENCE AND PREGNANCY OUTCOME IN A TERTIARY HEALTH CENTRE IN ABUJA, NIGERIA: A 4 YEAR REVIEW.

Background: Abruptio placentae remains a major cause of maternal and perinatal morbidity and mortality globally with poorer outcomes in developing countries like Nigeria. Even though most of its risk factors are known, t...

Download PDF file
  • EP ID EP672476
  • DOI -
  • Views 113
  • Downloads 0

How To Cite

Hadeel Ismail Mohsen (2019). IMMUNOHISTOCHEMICAL EXPRESSION OF CANCER STEM CELL MARKER (ALDH1) IN A PROSTATE CANCER. European Journal of Pharmaceutical and Medical Research, 6(1), 89-95. https://europub.co.uk/articles/-A-672476